Compare TG Therapeutics Inc (TGTX) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs US Bancorp — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while US Bancorp trades at $65.08 (market cap $100.17B). The key difference: US Bancorp is far larger — about 13.1× TG Therapeutics Inc's market cap, and US Bancorp pays a 3.24% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | USB | |
|---|---|---|
Market Cap | $7.64B | $100.17B |
Sector | Health | Financials |
52-Week High | $59.06 | $64.47 |
52-Week Low | $26.94 | $45.28 |
Enterprise Value | $7.84B | — |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
U.S. Bancorp (USB) trades at $64.95, up 1.18% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 12.83 and net income margin of 27.61%, while recent quarters have consistently beaten earnings estimates. Positive sentiment is driven by upbeat Q2 2026 results and analyst upgrades, though RSI levels indicate potential overbought conditions near-term.
The outlook remains favorable with a consensus price target of $70.27, implying 8% upside, supported by dividend stability and lending growth. Risks include interest rate sensitivity and insider selling, but institutional accumulation and robust profitability underpin a constructive view for investors seeking value in regional banking.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
